In the TCGA dataset, alterations were detected in ARID1A in low grade glioma (SNV: 3.9%, 11/283; deletion: 0.4%, 1/283) and glioblastoma (SNV: 0.7%, 2/281) [25, 26]. Here, ARID1A is linked to central nervous system cancer.